查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1654376

癌症诊断市场规模、份额、趋势分析报告，按产品类型、应用、最终用途、测试类型、范围、地区、细分预测，2025-2030 年

Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product, By Type, By Application, By End-use, By Test Type, By Coverage, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 200 Pages | 商品交期: 2-10个工作天内

价格

癌症诊断市场的成长和趋势

根据Grand View Research, Inc.的新报告，到2030年全球癌症诊断市场规模预计将达到1,550.7亿美元。预计 2025 年至 2030 年间，市场复合年增长率为 6.14%。一些组织进行的癌症意识提升计划数量不断增加是推动全球诊断产品需求增加的主要因素。国家子宫颈癌联盟、世界卫生组织、疾病预防控制中心、美国预防服务工作小组等为增加子宫颈癌筛检而建立的伙伴关係和协作是预计在预测期内推动市场成长的关键因素之一。

因此，一些国家正在采取措施，增加筛检以便早期诊断并支持现有患者。例如，印度政府为治疗期间需要帮助的患者推出了「Ayushman Bharat」和总理国家救助基金。同样，印度政府生物技术部与英国癌症研究中心签署了一项合同，研究更便宜的诊断和治疗方法。

液态生物检体溶液由于其易于临床应用，越来越多地被用作 MCED 测试。近年来，综合、多种癌症诊断方法已获得监管部门的核准。该领域的突破性进展和早期检测的持续研究正在促进市场的成长。此外，循环肿瘤DNA、细胞外囊泡和循环性肿瘤细胞等技术正在为更好的癌症治疗铺平道路。我们的多功能技术可以提供综合解决方案，以充分发挥液态生物检体的潜力。

使用伴同性诊断的优点在于可以整体减少製药和诊断公司所需的时间和成本。开发和商业化一种新分子通常需要10到15年的时间。诊断技术和药物的共同开发加快了监管核准流程并大大降低了成本。自2016年FDA发布治疗和IVD伴同性诊断发展的指引草案以来，许多厂商纷纷鼓励肿瘤领域伴同性诊断的发展。预计这将对预测期内的市场成长产生积极影响。

癌症诊断市场报告重点

  • 根据产品，消耗品部分将在 2024 年占据市场的最大份额，达到 58.4%，预计在预测期内将以最快的速度成长。
  • 根据类型，体外诊断 (IVD) 部门在 2024 年占有 52.0% 的份额。
  • 由于提高公众意识的倡议不断增加以及研发活动的不断增加，预计乳癌应用领域在预测期内将大幅成长。
  • 根据最终用途，提供高效门诊病人服务的实验室部门占据市场主导地位。由于住院患者数量的增加，预计未来几年医院部门将显着成长。
  • 由于活检具有多种益处，包括早期发现疾病，预计切片检查领域将以显着的速度增长。
  • 由于核准的新诊断测试数量不断增加，北美在 2024 年占据了全球癌症诊断市场的主导地位。
  • 由于普及率的提高和主要参与企业的存在，预计亚太地区在未来几年将显着增长。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素
    • 癌症发生率上升
    • 技术进步
    • 增加公营和私营部门的倡议
    • 广泛研究和开发新的检测解决方案
  • 市场限制因素分析
    • 诊断成像成本高昂
    • 辐射暴露可能会限制电脑断层扫描的使用
    • 再生诊断影像系统的采用日益广泛
  • 商业环境分析
    • 依因素（政治/法律、经济/技术）进行 SWOT 分析
    • 波特五力分析
    • COVID-19影响分析
  • 市场机会分析
    • 个人化医疗和伴同性诊断的出现
  • 人工智慧在癌症诊断中的地位
    • 市场趋势：
    • 新产品开发
    • 主要参与企业及其产品列表
  • 固态和液态生物检体切片检查的比较分析
  • 血液诊断的趋势
  • CfDNA 检测前景
    • 核准检查
    • 临床试验现状
  • NGS检测概况
  • 早期检测的趋势
    • 及早发现无症状患者
    • 有症状的患者
    • 復发检测
  • 美国癌症研究津贴状况
    • 按癌症类型
    • 按状态
  • 专利申请状况
  • 对未来科技如何融入病人照护途径的定性分析

第四章 产品业务分析

  • 癌症诊断市场：产品变异分析
  • 装置
    • 2018-2030 年装备市场
    • 基于病理学的仪器
    • 影像设备
    • 其他的
  • 耗材
    • 消耗品市场，2018-2030
  • 服务
    • 服务市场，2018-2030

第五章 类型业务分析

  • 癌症诊断市场：类型变异分析
  • 体外诊断
    • 体外诊断市场，2018-2030
    • 2018 年至 2030 年 IVD 市场（按类型）
    • 2018 年至 2030 年 IVD 市场（依技术划分）
  • LDDT
    • LDT 市场，2018-2030
  • 影像学
    • 影像市场，2018 - 2030
    • 磁振造影（MRI）
    • 电脑断层扫描 (CT)
    • 正子断层扫描 (PET)
    • 乳房X光检查
    • 超音波
    • 其他的

第六章 应用业务分析

  • 癌症诊断市场：应用趋势分析
  • 乳癌
    • 乳癌市场，2018-2030
  • 大肠直肠癌
    • 大肠直肠癌市场，2018 - 2030 年
  • 子宫颈癌
    • 子宫颈癌市场，2018 - 2030
  • 肺癌
    • 肺癌市场，2018-2030
  • 摄护腺癌
    • 摄护腺癌市场，2018-2030
  • 皮肤癌
    • 皮肤癌市场，2018-2030
  • 血癌
    • 血液肿瘤市场，2018 - 2030 年
  • 肾癌
    • 肾癌市场，2018-2030
  • 肝癌
    • 肝癌市场，2018 - 2030
  • 胰臟癌
    • 胰臟癌市场，2018 - 2030
  • 卵巢癌
    • 卵巢癌市场，2018 - 2030 年
  • 其他的
    • 其他市场，2018-2030

第 7 章 最终用途业务分析

  • 癌症诊断市场：最终用途变异分析
  • 医院
    • 医院市场，2018-2030
  • 实验室
    • 实验室市场，2018-2030
  • 其他的
    • 其他癌症诊断市场，2018 - 2030 年

第 8 章 测试类型业务分析

  • 癌症诊断市场：检测类型变化分析
  • 切片检查
    • 2018-2030 年切片检查市场
    • 细针穿刺
    • 芯切片检查
    • 手术切片检查
    • 皮肤切片检查/穿刺切片检查
    • 其他的
  • 其他的
    • 其他癌症诊断市场，2018 - 2030 年

第九章 产品业务分析

  • 癌症诊断市场：产品变异分析
  • 装置
    • 2018-2030 年装备市场
  • 耗材套件和试剂
    • 耗材套件和试剂市场，2018-2030
  • 软体和服务
    • 软体与服务市场，2018-2030

第十章 业务范围分析

  • 癌症诊断市场：目标范围变化分析
  • 公共保险
    • 公共保险市场，2018-2030 年
  • 私人保险
    • 私人保险市场，2018-2030 年

第十一章 区域经营分析

  • 2024 年及 2030 年市场占有率
  • 北美洲
    • 2018 至 2030 年北美癌症诊断市场
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲癌症诊断市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018 至 2030 年亚太地区癌症诊断市场
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018 至 2030 年拉丁美洲癌症诊断市场
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 2018 年至 2030 年中东和非洲癌症诊断市场
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十二章 竞争格局

  • 公司分类
  • 2024 年癌症诊断市场占有率分析
  • 公司简介
    • Abbott
    • Ge Healthcare
    • F. Hoffmann-la Roche Ltd.
    • Qiagen
    • Bd
    • Siemens Healthcare Gmbh
    • Thermo Fisher Scientific, Inc.
    • Hologic, Inc.
    • Koninklijke Philips Nv（Philips）
    • Illumina, Inc.
    • Agilent Technologies Inc
    • Foundation Medicine
    • Danaher Corporation
    • Bio-rad Laboratories, Inc
    • Perkinelmer Inc
    • Myriad Genetics, Inc.
    • Sysmex Corporation
    • Neogenomics Laboratories, Inc
    • Exact Sciences Corporation
    • Grail
    • Guardant Health Inc,.
    • Tempus
    • Delfi Diagnostics
    • Adela, Inc
    • Clearnote Health
    • Natera
  • 战略地图
    • 扩张
    • 获得
    • 合作
    • 疾病类型/药物类别发布
    • 伙伴关係
    • 其他的
  • 主要公司分销模式分析
  • 2024 年美国癌症诊断市场竞争热图分析
  • 2024 年英国癌症诊断市场竞争热图分析
  • 原发诊断不明的癌症公司名单
  • Guardant 检查评估

第 13 章结论/要点

Product Code: GVR-1-68038-213-6

Cancer Diagnostics Market Growth & Trends:

The global cancer diagnostics market size is anticipated to reach USD 155.07 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.14% from 2025 to 2030. Increasing number of programs to raise awareness about cancer by several organizations is a major factor accountable for increased demand for diagnostic products worldwide. Partnerships and collaborations undertaken by the National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, & others for increasing cervical cancer screening are among the major factors expected to boost market growth during the forecast period.

Several countries have thus undertaken measures to increase screening for early diagnosis and help existing patients. For instance, Ayushman Bharat and the Prime Minister's National Relief Fund was initiated by the Indian government for patients who require assistance during the treatment. Similarly, the Indian government's Department of Biotechnology signed a contract with Cancer Research UK to conduct research for affordable approaches to diagnosis and treatment.

Liquid biopsy solutions are being increasingly adopted as MCED tests as they are easily accessible for clinical applications. In recent years, they have gained regulatory approval with comprehensive and multi-cancer diagnostic approaches. Breakthrough advancements in the field and ongoing studies for early detection are contributing to market growth. Moreover, technologies such as circulating tumor DNA, extracellular vesicles, and circulating tumor cells are paving the way for better cancer care. Versatile technologies can provide integrated solutions for maximizing the potential of liquid biopsy.

Advantage of using companion diagnostics is the overall reduction in time and costs incurred by pharmaceutical and diagnostic companies. The time required to develop and commercialize a novel molecule generally consists of 10 to 15 years. Co-development of diagnostics and drugs facilitates accelerated regulatory approval processes, which significantly reduces costs. . Since the FDA guidance draft for the development of an IVD companion diagnostic device with a therapeutic product was published in 2016, many manufacturers encourage the development of companion diagnostic assays in the field of oncology. This is anticipated to positively impact market growth during the forecast period.

Cancer Diagnostics Market Report Highlights:

  • Based on product, the consumables segment held the largest share of 58.4% in 2024 and is anticipated to grow at the fastest growth rate over the forecast period
  • Based on type, in vitro diagnostics (IVD) segment dominated the in 2024 with a share of 52.0% due to the increasing adoption of IVD owing to the rise in testing amid COVID-19 pandemic.
  • The breast cancer application segment is expected to grow lucratively over the forecast period due to growth in initiatives to spread awareness across the population and increase in R&D activities.
  • Based on end-use, the laboratories segment dominated the market due to efficient outpatient services. The hospitals segment is forecasted grow at a significant rate over the coming years attributed to an increase in the admittance of patients in hospitals
  • The biopsy segment is anticipated to grow at a significant growth rate due to various benefits associated with the test, including early detection of the disease
  • North America dominated the global cancer diagnostics market in 2024, owing to rise in the number of approvals of new diagnostic tests
  • The Asia Pacific is expected to grow considerably in the future owing to due to the rising prevalence and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product And Type Snapshot
  • 2.3. Application And End Use Snapshot
  • 2.4. Test Type And Coveragesnapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Prevalence Of Cancer
    • 3.4.2. Technological Advancements
    • 3.4.3. Rising Initiatives Undertaken By Public And Private Organizations
    • 3.4.4. Extensive R&d For The Development Of Novel Testing Solutions
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost Of Diagnostic Imaging
    • 3.5.2. Radiation Exposure Likely To Limit Usage Of Ct Scans
    • 3.5.3. Rising Adoption Of Refurbished Diagnostic Imaging Systems
  • 3.6. Business Environment Analysis
    • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis
  • 3.7. Market Opportunity Analysis
    • 3.7.1. Advent Of Personalized Medicine And Companion Diagnostics
  • 3.8. Artificial Intelligence Landscape For Cancer Diagnostics
    • 3.8.1. Market Trends:
    • 3.8.2. New Product Development
    • 3.8.3. List Of Key Players With Their Offerings
  • 3.9. Comparative Analysis Of Solid Vs. Liquid Biopsies
  • 3.10. Trends In Blood-based Diagnostics
  • 3.11. Cfdna Test Landscape
    • 3.11.1. Approved Tests
    • 3.11.2. Clinical Trials Landscape
  • 3.12. Ngs Tests Landscape
  • 3.13. Trends In Early Detection
    • 3.13.1. Early Detection In Asymptomatic Patients
    • 3.13.2. Symptomatic Patients
    • 3.13.3. Recurrence Detection
  • 3.14. U.S. Cancer Research Grants Funding Landscape
    • 3.14.1. By Cancer Type
    • 3.14.2. By State
  • 3.15. Patent Filing Landscape
  • 3.16. Qualitative Analysis Of How Upcoming Technologies Fit Into Patient Pathways

Chapter 4. Product Business Analysis

  • 4.1. Cancer Diagnostics Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2. Pathology Based-instruments
      • 4.2.2.1. Slide Staining Systems
        • 4.2.2.1.1. Slide Staining Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.2. Tissue Processing Systems
        • 4.2.2.2.1. Tissue Processing Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.3. Cell Processors
        • 4.2.2.3.1. Cell Processors Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.4. Pcr Instruments
        • 4.2.2.4.1. Pcr Instruments Market, 2018 - 2030 (USD Billion)
      • 4.2.2.5. Ngs Instruments
        • 4.2.2.5.1. Ngs Instruments Market, 2018 - 2030 (USD Billion)
      • 4.2.2.6. Microarrays
        • 4.2.2.6.1. Microarrays Market, 2018 - 2030 (USD Billion)
      • 4.2.2.7. Other Pathology-based Instruments
        • 4.2.2.7.1. Other Pathology-based Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.3. Imaging Instruments
    • 4.2.4. Others
  • 4.3. Consumables
    • 4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
  • 4.4. Services
    • 4.4.1. Services Market, 2018 - 2030 (USD Billion)

Chapter 5. Type Business Analysis

  • 5.1. Cancer Diagnostics Market: Type Movement Analysis
  • 5.2. IVD
    • 5.2.1. IVD Market, 2018 - 2030 (USD Billion)
    • 5.2.2. IVD Market, By Type 2018 - 2030 (USD Billion)
      • 5.2.2.1. Diagnosis
        • 5.2.2.1.1. Diagnosis Market, 2018 - 2030 (USD Billion)
      • 5.2.2.2. Early Detection
        • 5.2.2.2.1. Early Detection Market, 2018 - 2030 (USD Billion)
      • 5.2.2.3. Therapy Selection
        • 5.2.2.3.1. Therapy Selection Market, 2018 - 2030 (USD Billion)
      • 5.2.2.4. Monitoring
        • 5.2.2.4.1. Monitoring Market, 2018 - 2030 (USD Billion)
    • 5.2.3. IVD Market, By Technology 2018 - 2030 (USD Billion)
      • 5.2.3.1. Polymerase Chain Reaction (Pcr)
        • 5.2.3.1.1. Polymerase Chain Reaction (Pcr) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.2. In Situ Hybridization (Ish)
        • 5.2.3.2.1. In Situ Hybridization (Ish) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.3. Immunohistochemistry (Ihc)
        • 5.2.3.3.1. Immunohistochemistry (Ihc) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.4. Next-generation Sequencing (Ngs)
        • 5.2.3.4.1. Next-generation Sequencing (Ngs) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.5. Microarrays
        • 5.2.3.5.1. Microarrays Market, 2018 - 2030 (USD Billion)
      • 5.2.3.6. Flow Cytometry
        • 5.2.3.6.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
      • 5.2.3.7. Immunoassays
        • 5.2.3.7.1. Immunoassays Market, 2018 - 2030 (USD Billion)
      • 5.2.3.8. Other IVD Testing Technologies
        • 5.2.3.8.1. Other IVD Testing Technologies Market, 2018 - 2030 (USD Billion)
  • 5.3. LDT
    • 5.3.1. LDT Market, 2018 - 2030 (USD Billion)
  • 5.4. Imaging
    • 5.4.1. Imaging Market, 2018 - 2030 (USD Billion)
    • 5.4.2. Magnetic Resonance Imaging (Mri)
      • 5.4.2.1. Magnetic Resonance Imaging (Mri) Market, 2018 - 2030 (USD Billion)
    • 5.4.3. Computed Tomography (Ct)
      • 5.4.3.1. Computed Tomography (Ct) Market, 2018 - 2030 (USD Billion)
    • 5.4.4. Positron Emission Tomography (Pet)
      • 5.4.4.1. Positron Emission Tomography (Pet) Market, 2018 - 2030 (USD Billion)
    • 5.4.5. Mammography
      • 5.4.5.1. Mammography Market, 2018 - 2030 (USD Billion)
    • 5.4.6. Ultrasound
      • 5.4.6.1. Ultrasound Market, 2018 - 2030 (USD Billion)
    • 5.4.7. Others
      • 5.4.7.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Application Business Analysis

  • 6.1. Cancer Diagnostics Market: Application Movement Analysis
  • 6.2. Breast Cancer
    • 6.2.1. Breast Cancer Market, 2018 - 2030 (USD Billion)
  • 6.3. Colorectal Cancer
    • 6.3.1. Colorectal Cancer Market, 2018 - 2030 (USD Billion)
  • 6.4. Cervical Cancer
    • 6.4.1. Cervical Cancer Market, 2018 - 2030 (USD Billion)
  • 6.5. Lung Cancer
    • 6.5.1. Lung Cancer Market, 2018 - 2030 (USD Billion)
  • 6.6. Prostate Cancer
    • 6.6.1. Prostate Cancer Market, 2018 - 2030 (USD Billion)
  • 6.7. Skin Cancer
    • 6.7.1. Skin Cancer Market, 2018 - 2030 (USD Billion)
  • 6.8. Blood Cancer
    • 6.8.1. Blood Cancer Market, 2018 - 2030 (USD Billion)
  • 6.9. Kidney Cancer
    • 6.9.1. Kidney Cancer Market, 2018 - 2030 (USD Billion)
  • 6.10. Liver Cancer
    • 6.10.1. Liver Cancer Market, 2018 - 2030 (USD Billion)
  • 6.11. Pancreatic Cancer
    • 6.11.1. Pancreatic Cancer Market, 2018 - 2030 (USD Billion)
  • 6.12. Ovarian Cancer
    • 6.12.1. Ovarian Cancer Market, 2018 - 2030 (USD Billion)
  • 6.13. Others
    • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. End Use Business Analysis

  • 7.1. Cancer Diagnostics Market: End Use Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 7.3. Laboratories
    • 7.3.1. Laboratories Market, 2018 - 2030 (USD Billion)
  • 7.4. Others
    • 7.4.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 8. Test Type Business Analysis

  • 8.1. Cancer Diagnostics Market: Test Type Movement Analysis
  • 8.2. Biopsy
    • 8.2.1. Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.2. Fine-needle Aspiration
      • 8.2.2.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
    • 8.2.3. Core Biopsy
      • 8.2.3.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.4. Surgical Biopsy
      • 8.2.4.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.5. Skin Biopsy /punch Biopsy
      • 8.2.5.1. Skin Biopsy /punch Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.6. Others
      • 8.2.6.1. Others Market, 2018 - 2030 (USD Billion)
  • 8.3. Others
    • 8.3.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 9. Product Business Analysis

  • 9.1. Cancer Diagnostics Market: Product Movement Analysis
  • 9.2. Instruments
    • 9.2.1. Instruments Market, 2018 - 2030 (USD Billion)
  • 9.3. Consumables Kits And Reagents
    • 9.3.1. Consumables Kits And Reagents Market, 2018 - 2030 (USD Billion)
  • 9.4. Software And Services
    • 9.4.1. Software And Services Market, 2018 - 2030 (USD Billion)

Chapter 10. Coverage Business Analysis

  • 10.1. Cancer Diagnostics Market: Coverage Movement Analysis
  • 10.2. Public Insurance
    • 10.2.1. Public Insurance Market, 2018 - 2030 (USD Billion)
  • 10.3. Private Insurance
    • 10.3.1. Private Insurance Market, 2018 - 2030 (USD Billion)

Chapter 11. Regional Business Analysis

  • 11.1. Cancer Diagnostics Market Share By Region, 2024 & 2030
  • 11.2. North America
    • 11.2.1. North America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.2.2. U.S.
      • 11.2.2.1. Key Country Dynamics
      • 11.2.2.2. Target Disease Prevalence
      • 11.2.2.3. Competitive Scenario
      • 11.2.2.4. Regulatory Framework
      • 11.2.2.5. Reimbursement Scenario
      • 11.2.2.6. U.S. Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.2.3. Canada
      • 11.2.3.1. Key Country Dynamics
      • 11.2.3.2. Target Disease Prevalence
      • 11.2.3.3. Competitive Scenario
      • 11.2.3.4. Regulatory Framework
      • 11.2.3.5. Reimbursement Scenario
      • 11.2.3.6. Canada Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3. Europe
    • 11.3.1. Europe Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.2. Germany
      • 11.3.2.1. Key Country Dynamics
      • 11.3.2.2. Target Disease Prevalence
      • 11.3.2.3. Competitive Scenario
      • 11.3.2.4. Regulatory Framework
      • 11.3.2.5. Reimbursement Scenario
      • 11.3.2.6. Germany Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.3. Uk
      • 11.3.3.1. Key Country Dynamics
      • 11.3.3.2. Target Disease Prevalence
      • 11.3.3.3. Competitive Scenario
      • 11.3.3.4. Regulatory Framework
      • 11.3.3.5. Reimbursement Scenario
      • 11.3.3.6. Uk Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.4. France
      • 11.3.4.1. Key Country Dynamics
      • 11.3.4.2. Target Disease Prevalence
      • 11.3.4.3. Competitive Scenario
      • 11.3.4.4. Regulatory Framework
      • 11.3.4.5. Reimbursement Scenario
      • 11.3.4.6. France Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.5. Italy
      • 11.3.5.1. Key Country Dynamics
      • 11.3.5.2. Target Disease Prevalence
      • 11.3.5.3. Competitive Scenario
      • 11.3.5.4. Regulatory Framework
      • 11.3.5.5. Reimbursement Scenario
      • 11.3.5.6. Italy Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.6. Spain
      • 11.3.6.1. Key Country Dynamics
      • 11.3.6.2. Target Disease Prevalence
      • 11.3.6.3. Competitive Scenario
      • 11.3.6.4. Regulatory Framework
      • 11.3.6.5. Reimbursement Scenario
      • 11.3.6.6. Spain Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.7. Denmark
      • 11.3.7.1. Key Country Dynamics
      • 11.3.7.2. Target Disease Prevalence
      • 11.3.7.3. Competitive Scenario
      • 11.3.7.4. Regulatory Framework
      • 11.3.7.5. Reimbursement Scenario
      • 11.3.7.6. Denmark Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.8. Sweden
      • 11.3.8.1. Key Country Dynamics
      • 11.3.8.2. Target Disease Prevalence
      • 11.3.8.3. Competitive Scenario
      • 11.3.8.4. Regulatory Framework
      • 11.3.8.5. Reimbursement Scenario
      • 11.3.8.6. Sweden Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.3.9. Norway
      • 11.3.9.1. Key Country Dynamics
      • 11.3.9.2. Target Disease Prevalence
      • 11.3.9.3. Competitive Scenario
      • 11.3.9.4. Regulatory Framework
      • 11.3.9.5. Reimbursement Scenario
      • 11.3.9.6. Norway Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4. Asia Pacific
    • 11.4.1. Asia Pacific Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.2. Japan
      • 11.4.2.1. Key Country Dynamics
      • 11.4.2.2. Target Disease Prevalence
      • 11.4.2.3. Competitive Scenario
      • 11.4.2.4. Regulatory Framework
      • 11.4.2.5. Reimbursement Scenario
      • 11.4.2.6. Japan Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.3. China
      • 11.4.3.1. Key Country Dynamics
      • 11.4.3.2. Target Disease Prevalence
      • 11.4.3.3. Competitive Scenario
      • 11.4.3.4. Regulatory Framework
      • 11.4.3.5. Reimbursement Scenario
      • 11.4.3.6. China Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.4. India
      • 11.4.4.1. Key Country Dynamics
      • 11.4.4.2. Target Disease Prevalence
      • 11.4.4.3. Competitive Scenario
      • 11.4.4.4. Regulatory Framework
      • 11.4.4.5. Reimbursement Scenario
      • 11.4.4.6. India Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.5. South Korea
      • 11.4.5.1. Key Country Dynamics
      • 11.4.5.2. Target Disease Prevalence
      • 11.4.5.3. Competitive Scenario
      • 11.4.5.4. Regulatory Framework
      • 11.4.5.5. Reimbursement Scenario
      • 11.4.5.6. South Korea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.6. Australia
      • 11.4.6.1. Key Country Dynamics
      • 11.4.6.2. Target Disease Prevalence
      • 11.4.6.3. Competitive Scenario
      • 11.4.6.4. Regulatory Framework
      • 11.4.6.5. Reimbursement Scenario
      • 11.4.6.6. Australia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.4.7. Thailand
      • 11.4.7.1. Key Country Dynamics
      • 11.4.7.2. Target Disease Prevalence
      • 11.4.7.3. Competitive Scenario
      • 11.4.7.4. Regulatory Framework
      • 11.4.7.5. Reimbursement Scenario
      • 11.4.7.6. Thailand Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5. Latin America
    • 11.5.1. Latin America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.5.2. Brazil
      • 11.5.2.1. Key Country Dynamics
      • 11.5.2.2. Target Disease Prevalence
      • 11.5.2.3. Competitive Scenario
      • 11.5.2.4. Regulatory Framework
      • 11.5.2.5. Reimbursement Scenario
      • 11.5.2.6. Brazil Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.5.3. Mexico
      • 11.5.3.1. Key Country Dynamics
      • 11.5.3.2. Target Disease Prevalence
      • 11.5.3.3. Competitive Scenario
      • 11.5.3.4. Regulatory Framework
      • 11.5.3.5. Reimbursement Scenario
      • 11.5.3.6. Mexico Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.5.4. Argentina
      • 11.5.4.1. Key Country Dynamics
      • 11.5.4.2. Target Disease Prevalence
      • 11.5.4.3. Competitive Scenario
      • 11.5.4.4. Regulatory Framework
      • 11.5.4.5. Reimbursement Scenario
      • 11.5.4.6. Argentina Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6. Mea
    • 11.6.1. Mea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.2. South Africa
      • 11.6.2.1. Key Country Dynamics
      • 11.6.2.2. Target Disease Prevalence
      • 11.6.2.3. Competitive Scenario
      • 11.6.2.4. Regulatory Framework
      • 11.6.2.5. Reimbursement Scenario
      • 11.6.2.6. South Africa Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.3. Saudi Arabia
      • 11.6.3.1. Key Country Dynamics
      • 11.6.3.2. Target Disease Prevalence
      • 11.6.3.3. Competitive Scenario
      • 11.6.3.4. Regulatory Framework
      • 11.6.3.5. Reimbursement Scenario
      • 11.6.3.6. Saudi Arabia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.4. Uae
      • 11.6.4.1. Key Country Dynamics
      • 11.6.4.2. Target Disease Prevalence
      • 11.6.4.3. Competitive Scenario
      • 11.6.4.4. Regulatory Framework
      • 11.6.4.5. Reimbursement Scenario
      • 11.6.4.6. Uae Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
    • 11.6.5. Kuwait
      • 11.6.5.1. Key Country Dynamics
      • 11.6.5.2. Target Disease Prevalence
      • 11.6.5.3. Competitive Scenario
      • 11.6.5.4. Regulatory Framework
      • 11.6.5.5. Reimbursement Scenario
      • 11.6.5.6. Kuwait Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 12. Competitive Landscape

  • 12.1. Company Categorization
  • 12.2. Cancer Diagnostics Market Share Analysis, 2024
  • 12.3. Company Profiles
    • 12.3.1. Abbott
      • 12.3.1.1. Company Overview
      • 12.3.1.2. Financial Performance
      • 12.3.1.3. Product Benchmarking
      • 12.3.1.4. Strategic Initiatives
    • 12.3.2. Ge Healthcare
      • 12.3.2.1. Company Overview
      • 12.3.2.2. Financial Performance
      • 12.3.2.3. Product Benchmarking
      • 12.3.2.4. Strategic Initiatives
    • 12.3.3. F. Hoffmann-la Roche Ltd.
      • 12.3.3.1. Company Overview
      • 12.3.3.2. Financial Performance
      • 12.3.3.3. Product Benchmarking
      • 12.3.3.4. Strategic Initiatives
    • 12.3.4. Qiagen
      • 12.3.4.1. Company Overview
      • 12.3.4.2. Financial Performance
      • 12.3.4.3. Product Benchmarking
      • 12.3.4.4. Strategic Initiatives
    • 12.3.5. Bd
      • 12.3.5.1. Company Overview
      • 12.3.5.2. Financial Performance
      • 12.3.5.3. Product Benchmarking
      • 12.3.5.4. Strategic Initiatives
    • 12.3.6. Siemens Healthcare Gmbh
      • 12.3.6.1. Company Overview
      • 12.3.6.2. Financial Performance
      • 12.3.6.3. Product Benchmarking
      • 12.3.6.4. Strategic Initiatives
    • 12.3.7. Thermo Fisher Scientific, Inc.
      • 12.3.7.1. Company Overview
      • 12.3.7.2. Financial Performance
      • 12.3.7.3. Product Benchmarking
      • 12.3.7.4. Strategic Initiatives
    • 12.3.8. Hologic, Inc.
      • 12.3.8.1. Company Overview
      • 12.3.8.2. Financial Performance
      • 12.3.8.3. Product Benchmarking
      • 12.3.8.4. Strategic Initiatives
    • 12.3.9. Koninklijke Philips N.v. (Philips)
      • 12.3.9.1. Company Overview
      • 12.3.9.2. Financial Performance
      • 12.3.9.3. Product Benchmarking
      • 12.3.9.4. Strategic Initiatives
    • 12.3.10. Illumina, Inc.
      • 12.3.10.1. Company Overview
      • 12.3.10.2. Financial Performance
      • 12.3.10.3. Product Benchmarking
      • 12.3.10.4. Strategic Initiatives
    • 12.3.11. Agilent Technologies Inc
      • 12.3.11.1. Company Overview
      • 12.3.11.2. Financial Performance
      • 12.3.11.3. Product Benchmarking
      • 12.3.11.4. Strategic Initiatives
    • 12.3.12. Foundation Medicine
      • 12.3.12.1. Company Overview
      • 12.3.12.2. Financial Performance
      • 12.3.12.3. Product Benchmarking
      • 12.3.12.4. Strategic Initiatives
    • 12.3.13. Danaher Corporation
      • 12.3.13.1. Company Overview
      • 12.3.13.2. Financial Performance
      • 12.3.13.3. Product Benchmarking
      • 12.3.13.4. Strategic Initiatives
    • 12.3.14. Bio-rad Laboratories, Inc
      • 12.3.14.1. Company Overview
      • 12.3.14.2. Financial Performance
      • 12.3.14.3. Product Benchmarking
      • 12.3.14.4. Strategic Initiatives
    • 12.3.15. Perkinelmer Inc
      • 12.3.15.1. Company Overview
      • 12.3.15.2. Financial Performance
      • 12.3.15.3. Product Benchmarking
      • 12.3.15.4. Strategic Initiatives
    • 12.3.16. Myriad Genetics, Inc.
      • 12.3.16.1. Company Overview
      • 12.3.16.2. Financial Performance
      • 12.3.16.3. Product Benchmarking
      • 12.3.16.4. Strategic Initiatives
    • 12.3.17. Sysmex Corporation
      • 12.3.17.1. Company Overview
      • 12.3.17.2. Financial Performance
      • 12.3.17.3. Product Benchmarking
      • 12.3.17.4. Strategic Initiatives
    • 12.3.18. Neogenomics Laboratories, Inc
      • 12.3.18.1. Company Overview
      • 12.3.18.2. Financial Performance
      • 12.3.18.3. Product Benchmarking
      • 12.3.18.4. Strategic Initiatives
    • 12.3.19. Exact Sciences Corporation
      • 12.3.19.1. Company Overview
      • 12.3.19.2. Financial Performance
      • 12.3.19.3. Product Benchmarking
      • 12.3.19.4. Strategic Initiatives
    • 12.3.20. Grail
      • 12.3.20.1. Company Overview
      • 12.3.20.2. Financial Performance
      • 12.3.20.3. Product Benchmarking
      • 12.3.20.4. Strategic Initiatives
    • 12.3.21. Guardant Health Inc,.
      • 12.3.21.1. Company Overview
      • 12.3.21.2. Financial Performance
      • 12.3.21.3. Product Benchmarking
      • 12.3.21.4. Strategic Initiatives
    • 12.3.22. Tempus
      • 12.3.22.1. Company Overview
      • 12.3.22.2. Financial Performance
      • 12.3.22.3. Product Benchmarking
      • 12.3.22.4. Strategic Initiatives
    • 12.3.23. Delfi Diagnostics
      • 12.3.23.1. Company Overview
      • 12.3.23.2. Financial Performance
      • 12.3.23.3. Product Benchmarking
      • 12.3.23.4. Strategic Initiatives
    • 12.3.24. Adela, Inc
      • 12.3.24.1. Company Overview
      • 12.3.24.2. Financial Performance
      • 12.3.24.3. Product Benchmarking
      • 12.3.24.4. Strategic Initiatives
    • 12.3.25. Clearnote Health
      • 12.3.25.1. Company Overview
      • 12.3.25.2. Financial Performance
      • 12.3.25.3. Product Benchmarking
      • 12.3.25.4. Strategic Initiatives
    • 12.3.26. Natera
      • 12.3.26.1. Company Overview
      • 12.3.26.2. Financial Performance
      • 12.3.26.3. Product Benchmarking
      • 12.3.26.4. Strategic Initiatives
  • 12.4. Strategy Mapping
    • 12.4.1. Expansion
    • 12.4.2. Acquisition
    • 12.4.3. Collaborations
    • 12.4.4. Disease Type/drug Class Launch
    • 12.4.5. Partnerships
    • 12.4.6. Others
  • 12.5. Distribution Model Analysis For Major Players
  • 12.6. Competitive Heat Map Analysis For U.S. Cancer Diagnostics Market, 2024
  • 12.7. Competitive Heat Map Analysis For Uk Cancer Diagnostics Market, 2024
  • 12.8. List Of Cancers Of Unknown Primary Diagnostics Companies
  • 12.9. Guardant Test Evaluation

Chapter 13. Conclusion/key Takeways

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global cancer diagnostics market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 5 Global cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 6 Global cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 7 Global cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 8 North America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 9 North America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 10 North America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 11 North America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 12 North America cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 13 North America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 14 North America cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 15 U.S. cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 16 U.S. cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 17 U.S. cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 18 U.S. cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 19 U.S. cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 20 U.S. cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 21 Canada cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 22 Canada cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 23 Canada cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Canada cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 25 Canada cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 26 Canada cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 27 Europe cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 28 Europe cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 29 Europe cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 30 Europe cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 31 Europe cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 32 Europe cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 33 Europe cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 34 UK cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 35 UK cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 36 UK cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 37 UK cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 38 UK cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 39 UK cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 40 Germany cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 41 Germany cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 42 Germany cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 43 Germany cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 44 Germany cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 45 Germany cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 46 France cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 47 France cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 48 France cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 49 France cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 50 France cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 51 France cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 52 Italy cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 53 Italy cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Italy cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 55 Italy cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 Italy cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 57 Italy cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 58 Spain cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 59 Spain cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 60 Spain cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 61 Spain cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 62 Spain cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 63 Spain cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 64 Denmark cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 65 Denmark cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 66 Denmark cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 67 Denmark cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 68 Denmark cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 69 Denmark cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 70 Sweden cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 71 Sweden cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 72 Sweden cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 73 Sweden cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 74 Sweden cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 75 Sweden cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 76 Norway cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 77 Norway cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 78 Norway cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 79 Norway cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 80 Norway cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 81 Norway cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 82 Asia Pacific cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 83 Asia Pacific cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 84 Asia Pacific cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 85 Asia Pacific cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 86 Asia Pacific cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 87 Asia Pacific cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 88 Asia Pacific cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 89 Japan cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 90 Japan cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 91 Japan cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 92 Japan cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 93 Japan cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 94 Japan cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 95 China cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 96 China cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 97 China cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 98 China cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 99 China cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 100 China cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 101 India cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 102 India cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 103 India cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 104 India cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 105 India cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 106 India cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 107 South Korea cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 108 South Korea cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 109 South Korea cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 110 South Korea cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 111 South Korea cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 112 South Korea cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 113 Thailand cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 114 Thailand cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 115 Thailand cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 116 Thailand cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 117 Thailand cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 118 Thailand cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 119 Australia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 120 Australia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 121 Australia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 122 Australia cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 123 Australia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 124 Australia cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 125 Latin America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 126 Latin America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 127 Latin America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 128 Latin America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 129 Latin America cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 130 Latin America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 131 Latin America cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 132 Brazil cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 133 Brazil cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 134 Brazil cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 135 Brazil cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 136 Brazil cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 137 Brazil cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 138 Mexico cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 139 Mexico cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 140 Mexico cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 141 Mexico cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 142 Mexico cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 143 Mexico cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 144 Argentina cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 145 Argentina cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 146 Argentina cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 147 Argentina cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 148 Argentina cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 149 Argentina cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 150 Middle East & Africa cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 151 Middle East & Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 152 Middle East & Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 153 Middle East & Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 154 Middle East & Africa cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 155 Middle East & Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 156 Middle East & Africa cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 157 South Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 158 South Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 159 South Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 160 South Africa cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 161 South Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 162 South Africa cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 163 Saudi Arabia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 164 Saudi Arabia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 165 Saudi Arabia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 166 Saudi Arabia cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 167 Saudi Arabia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 168 Saudi Arabia cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 169 UAE cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 170 UAE cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 171 UAE cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 172 UAE cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 173 UAE cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 174 UAE cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
  • Table 175 Kuwait cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 176 Kuwait cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 177 Kuwait cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 178 Kuwait cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
  • Table 179 Kuwait cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 180 Kuwait cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Cancer diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Product and type segment snapshot
  • Fig. 11 Application segment snapshot
  • Fig. 12 End use and test type segment snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Cancer diagnostics market value, 2024 (USD Billion)
  • Fig. 15 Market dynamics
  • Fig. 16 Incidence of most common cancers globally, 2024
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTLE analysis
  • Fig. 19 Cancer diagnostics market: Product outlook and key takeaways
  • Fig. 20 Cancer diagnostics market: Product movement analysis
  • Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 22 Pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Slide staining systems market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 24 Tissue processing systems market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 25 Cell processors market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 PCR instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 NGS instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Other pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Imaging instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 32 Consumables market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Kits & reagents market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 35 Probes market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Services market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Cancer diagnostics market: Type outlook and key takeaways
  • Fig. 39 Cancer diagnostics market: Type movement analysis
  • Fig. 40 IVD market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 41 Diagnosis market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Early detection market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Therapy selection market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Monitoring market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 45 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 46 In Situ Hybridization (ISH) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 Immunohistochemistry (IHC) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Next-generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 49 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 50 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 51 Immunoassays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 52 Other IVD testing technologies market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 LDT market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 54 Imaging market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 55 Magnetic Resonance Imaging (MRI) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 56 Computed Tomography (CT) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Positron Emission Tomography (PET) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 58 Mammography market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 59 Ultrasound market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 60 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Cancer diagnostics market: Application outlook and key takeaways
  • Fig. 62 Cancer diagnostics market: Application movement analysis
  • Fig. 63 Breast cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 64 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 66 Lung cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 67 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 68 Skin cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 69 Blood cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 70 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 71 Liver cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 72 Pancreatic cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 73 Ovarian cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 74 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 75 Cancer diagnostics market: End use outlook and key takeaways
  • Fig. 76 Cancer diagnostics market: End use movement analysis
  • Fig. 77 Hospitals market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 78 Laboratories market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 79 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 80 Cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 81 Cancer diagnostics market: Test type movement analysis
  • Fig. 82 Biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Fine-needle aspiration market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 84 Core biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 Surgical biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 86 Skin biopsy/punch biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 88 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Cancer diagnostics market: Coverage outlook and key takeaways
  • Fig. 90 Cancer diagnostics market: Coverage movement analysis
  • Fig. 91 Public insurance market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 92 Private insurance market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 93 Cancer Diagnostics Market revenue, by region, 2024 & 2030 (USD Billion)
  • Fig. 94 Regional marketplace: Key takeaways
  • Fig. 95 Regional marketplace: Key takeaways
  • Fig. 96 North America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 97 Key country dynamics
  • Fig. 98 U.S. cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 99 Cancer incidence, 2018 - 2030
  • Fig. 100 Ways to obtain coverage
  • Fig. 101 Key country dynamics
  • Fig. 102 Canada cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 103 Cancer incidence, 2018 - 2030
  • Fig. 104 Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 105 Key country dynamics
  • Fig. 106 UK cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 107 Cancer incidence, 2018 - 2030
  • Fig. 108 Key country dynamics
  • Fig. 109 Germany cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 110 Cancer incidence, 2018 - 2030
  • Fig. 111 Key country dynamics
  • Fig. 112 France cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 113 Cancer incidence, 2018 - 2030
  • Fig. 114 Key country dynamics
  • Fig. 115 Spain cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 116 Cancer incidence, 2018 - 2030
  • Fig. 117 Key country dynamics
  • Fig. 118 Italy cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 119 Cancer incidence, 2018 - 2030
  • Fig. 120 Key country dynamics
  • Fig. 121 Denmark cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 122 Target disease prevalence
  • Fig. 123 Key country dynamics
  • Fig. 124 Sweden cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 125 Five most common cancers in Sweden
  • Fig. 126 Key country dynamics
  • Fig. 127 Norway cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 128 Number of new cancer cases in 2020, both sexes, all ages
  • Fig. 129 Rest of Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 130 Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 131 Key country dynamics
  • Fig. 132 Japan cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 133 Cancer incidence, 2018 to 2030
  • Fig. 134 Key country dynamics
  • Fig. 135 China cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 136 Cancer incidence, 2018 to 2030
  • Fig. 137 China regulatory details
  • Fig. 138 Key country dynamics
  • Fig. 139 India cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 140 Cancer incidence, 2018 to 2030
  • Fig. 141 Key country dynamics
  • Fig. 142 Australia cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 143 Cancer incidence, 2018 to 2030
  • Fig. 144 Key country dynamics
  • Fig. 145 Thailand cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 146 Cancer incidence, 2020 to 2030
  • Fig. 147 Key country dynamics
  • Fig. 148 South Korea cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 149 Cancer incidence 2018 to 2030
  • Fig. 150 South Korean regulations in four hierarchical orders
  • Fig. 151 South Korea reimbursement scenario
  • Fig. 152 Rest of Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 153 Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 154 Key country dynamics
  • Fig. 155 Brazil cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 156 Estimated number of new cancer cases in Brazil
  • Fig. 157 Key country dynamics
  • Fig. 158 Mexico cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 159 Estimated number of new cancer cases in Mexico
  • Fig. 160 Key country dynamics
  • Fig. 161 Argentina cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 162 Estimated number of new cancer cases in Argentina
  • Fig. 163 Rest of Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 164 MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 165 Key country dynamics
  • Fig. 166 South Africa cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 167 Cancer prevalence-2018 - 2030
  • Fig. 168 Key country dynamics
  • Fig. 169 Saudi Arabia cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 170 Cancer prevalence-2018 - 2030
  • Fig. 171 Key country dynamics
  • Fig. 172 UAE cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 173 Cancer prevalence 2018 - 2030
  • Fig. 174 Key country dynamics
  • Fig. 175 Kuwait cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 176 Target disease prevalence
  • Fig. 177 Key payers in Kuwait
  • Fig. 178 Rest of MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 179 Key company categorization
  • Fig. 180 Company market share analysis, 2024
  • Fig. 181 Strategic framework
  • Fig. 182 Competitive heat map analysis for U.S.
  • Fig. 183 Competitive heat map analysis for UK